insights

Learn about cutting-edge science
and gain life-enhancing insights

Investors are starting to bet big on psychedelic medicine

Just weeks after the U.S. Food and Drug Administration approved Johnson & Johnson’s ketamine-like nasal spray for depression, a group of European technology investors just got together for the largest-ever private financing round for a psychedelic medicine biotech company, ATAI.

Read More »

Follow us
on Social Media